STOCK TITAN

Aptose Bioscienc Stock Price, News & Analysis

APTOF OTC

Welcome to our dedicated page for Aptose Bioscienc news (Ticker: APTOF), a resource for investors and traders seeking the latest updates and insights on Aptose Bioscienc stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aptose Bioscienc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aptose Bioscienc's position in the market.

Rhea-AI Summary
Aptose Biosciences reported Q1 2025 financial results and progress in its TUSCANY clinical trial for tuspetinib (TUS) in combination with venetoclax and azacitidine for frontline AML treatment. The trial showed promising results with 6 out of 7 patients achieving complete remissions across two dose cohorts (40mg and 80mg). Notably, two patients with TP53 mutations showed positive responses. The company reported a reduced net loss of $5.5M compared to $9.6M in Q1 2024, with cash reserves of $4.7M as of March 31, 2025. However, current funding only supports operations until end of May 2025. Aptose was delisted from Nasdaq in April 2025 and now trades on OTC Markets (APTOF) and TSX (APS). Research and development expenses decreased to $2.3M from $6.4M year-over-year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of Aptose Bioscienc (APTOF)?

The current stock price of Aptose Bioscienc (APTOF) is $1.65 as of May 8, 2025.
Aptose Bioscienc

OTC:APTOF

APTOF Rankings

APTOF Stock Data

2.04M